查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1931250

末期慢性肾臟病治疗市场依治疗类型、疾病阶段、最终用户、通路、作用机制及製剂划分，全球预测，2026-2032年

Late Stage Chronic Kidney Disease Therapeutics Market by Treatment Type, Disease Stage, End-User, Distribution Channel, Mechanism Of Action, Formulation - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，末期慢性肾臟病治疗市场规模将达到 130.2 亿美元，到 2026 年将成长至 141.6 亿美元，复合年增长率为 9.88%，到 2032 年将达到 252 亿美元。

关键市场统计数据
基准年 2025 130.2亿美元
预计年份：2026年 141.6亿美元
预测年份 2032 252亿美元
复合年增长率 (%) 9.88%

这是一本简洁而权威的入门读物，全面阐述了塑造现代慢性肾臟病治疗的临床复杂性、治疗创新和商业性需求。

末期慢性肾臟病（CKD）是患者照护的关键阶段，临床复杂性、医疗成本和治疗创新在此交会整合。晚期患者需要多方面的干预，包括肾臟替代治疗、优化药物治疗以控制併发症和合併症，以及肾臟移植评估。临床决策越来越注重在有限的医疗资源下，尽可能保留残余肾功能、降低心血管风险并提高病患的生活品质。

临床、监管和商业性动态的重大变革正在重塑终末期慢性肾臟病的治疗方法和优先事项。

末期慢性肾臟病领域正经历多项变革，这些变革正在重新定义治疗方法的研发、实施和评估方式。更精细的患者分层和生物标记的应用，使得更有针对性的干预策略成为可能，从而延缓疾病进展并减少透析的启动。同时，从先进的促红血球生成疗法到更具选择性的磷酸盐粘合剂和矿物质代谢调节剂，药物治疗的进步正在重新调整治疗目标，以减少住院和心血管事件的发生。

对 2025 年美国关税如何改变慢性肾臟病药物供应链的韧性、筹资策略和商业性经济进行了全面分析。

这些关税于2025年生效，对末期慢性肾臟病相关治疗药物的全球供应链造成了即时且连锁的压力。从受影响地区购买原料药、特殊辅料或成品製剂的製造商面临着到岸成本增加的困境，迫使财务和采购团队重新评估其筹资策略和库存缓衝。为因应这项挑战，各公司正加速近岸外包，实现供应商多元化，并增加对供应链可视性工具的投资，以降低风险敞口，确保注射剂和透析相关耗材等关键产品的持续供应。

深度細項分析揭示了治疗类型、疾病阶段、临床环境、通路、支付方、作用机制和剂型如何共同决定策略和价值实现。

精细化的细分框架揭示了不同治疗类别、疾病阶段、医疗机构、分销管道、支付方类型、作用机制和製剂形式所带来的独特需求驱动因素和商业性槓桿。治疗方法差异化定义了透析、药物治疗和移植路径，其中药物治疗进一步细分为抗高血压药物、促红血球生成素、磷酸盐粘合剂和维生素D类似物。这种细分突显了治疗目标和预期结果如何影响临床应用和商业化策略。将疾病阶段分为3期、4期和5期，为介入时机提供了临床蓝图。 3期和4期代表延缓疾病进展的机会，而5期则需要为肾臟替代治疗和复杂的护理协调做好准备。

区域分析概述了美洲、欧洲、中东和非洲以及亚太市场在采用率、报销和战略进入考量方面的差异

区域趋势决定了创新技术在哪些领域获得应用，以及治疗策略如何调整。在美洲，成熟的报销机制和一体化的医疗保健系统往往有利于快速推广疗效显着且成本效益高的临床创新技术，而完善的透析网络和移植项目则造就了需求热点地区。该地区的支付方谈判和卫生技术评估流程促进了基于真实世界数据和结果导向合约的製定，从而确保创新技术的广泛应用。

深入竞争考察差异化、伙伴关係、生产韧性和实证策略，协助企业在末期慢性肾臟病治疗领域建立领导地位。

慢性肾臟病（CKD）后期治疗药物的竞争格局呈现出多元化的特点：既有拥有深厚临床经验的成熟厂商，也有专注于机制创新、致力于研发新型药物的生物技术公司，还有着眼于医疗服务平台数位化的参与企业。现有厂商凭藉与透析服务提供者和医院建立的稳固关係、强大的分销网络以及丰富的上市后安全性数据，维持着市场地位。同时，新参与企业则优先考虑透过全新的作用机制、务实的试验设计以及针对未被满足的需求和潜在临床影响最大的目标患者群体，实现显着的差异化。

为产业领导者提供切实可行的策略建议，以协调证据产生、供应链韧性和支付方参与，从而加速技术采纳和普及。

企业应优先产生高品质的真实世界证据，以证明治疗性介入与降低住院率、延缓透析启动以及改善病患报告结局之间的关联。这些证据对于获得有利的报销条款和支持按绩效付费合约至关重要。同时，企业也应设计以病人为中心的支援项目，以解决用药依从性、多重疾病管理以及不同治疗方法涉及从医院过渡到家庭护理的治疗方案。

透明的调查方法，详细说明了数据三角验证、同行检验和情境分析等措施，以确保得出可靠且可操作的结论。

本分析整合了同行评审的临床文献、监管指南、公共声明以及与临床专家、支付方和采购负责人进行的经验证的检验，以确保对终末期慢性肾病药物的全面了解。调查方法将临床试验结果与真实世界的用药模式和供应链资讯进行三角验证，从而得出对商业化和政策制定具有实际意义的结论。来自第一线临床医生和护理管理人员的定性意见被用于阐明药物推广障碍和治疗路径限制，而供应商和经销商的观点则用于评估营运风险。

为将治疗创新转化为末期慢性肾臟病患者疗效的改善，需要对策略要务和相关人员的责任进行关键性综合分析。

末期慢性肾病药物正处于一个转折点，这个转折点受到科学进步、不断演变的护理模式和政策调整的影响。仅靠临床创新并不能保证产生影响。成功取决于差异化的治疗方法、稳健的供应链、以实证医学为基础的支付方合作，以及整合符合透析中心、医院和居家照护实际运作的交付模式。关税和地缘政治动盪带来的成本压力凸显了采取积极主动的筹资策略和合作合约解决方案的必要性，以确保患者能够获得维持生命的治疗。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 末期慢性肾臟病治疗市场（依治疗方法）

  • 透析
  • 药物治疗
    • 抗高血压药物
    • 红血球生成刺激因子
    • 磷酸盐粘合剂
    • 维生素D类似物
  • 移植

第九章 依疾病阶段分類的末期慢性肾臟病治疗市场

  • 第三阶段
  • 第四阶段
  • 第五阶段

第十章 末期慢性肾臟病药物市场（依最终用户划分）

  • 门诊手术中心
  • 透析中心
  • 居家医疗环境
  • 医院

第十一章 末期慢性肾臟病药物市场（依通路划分）

  • 离线
  • 在线的

第十二章 末期慢性肾臟病药物市场依作用机转划分

  • 红血球生成刺激
  • 磷酸盐结合
  • RAAS抑制
  • 维生素D受体激活

第十三章 依剂型分類的末期慢性肾臟病治疗市场

  • 注射
  • 口服

第十四章 各地区末期慢性肾臟病药物市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 末期慢性肾臟病药物市场（依组别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 各国末期慢性肾臟病药物市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

17. 美国末期慢性肾臟病药物市场

第十八章：中国末期慢性肾臟病治疗市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Akebia Therapeutics, Inc.
  • Amgen Inc.
  • Ardelyx, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Chinook Therapeutics, Inc.
  • Eli Lilly and Company
  • FibroGen, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • KBP Biosciences Co., Ltd.
  • Maze Therapeutics, Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • ProKidney, Inc.
  • Travere Therapeutics, Inc.
Product Code: MRR-7B550E008DE6

The Late Stage Chronic Kidney Disease Therapeutics Market was valued at USD 13.02 billion in 2025 and is projected to grow to USD 14.16 billion in 2026, with a CAGR of 9.88%, reaching USD 25.20 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 13.02 billion
Estimated Year [2026] USD 14.16 billion
Forecast Year [2032] USD 25.20 billion
CAGR (%) 9.88%

A concise authoritative introduction framing clinical complexity, therapeutic innovation, and commercial imperatives shaping late-stage chronic kidney disease care today

Late-stage chronic kidney disease (CKD) represents a pivotal junction in patient care where clinical complexity, care delivery costs, and therapeutic innovation converge. Patients progressing to advanced stages require multifaceted interventions that span renal replacement therapies, optimized pharmacotherapy to manage comorbidities and complications, and transplant evaluation. Clinical decision-making increasingly emphasizes preserving residual renal function, mitigating cardiovascular risk, and improving quality of life while navigating constrained health-system resources.

Over recent years, breakthroughs in pharmacologic mechanisms and care models have reshaped treatment algorithms and stakeholder expectations. At the same time, payers and providers are adapting to new cost structures and outcome-based contracting models that influence access to novel agents and supportive technologies. For industry leaders, understanding the interplay between clinical efficacy, safety profiles, delivery settings, and reimbursement pathways is essential to design credible value propositions and to prioritize investments that will deliver measurable patient and system benefits.

This executive summary synthesizes the most consequential shifts in late-stage CKD therapeutics, evaluates how U.S. tariff measures in 2025 are altering supply chain and commercial dynamics, and highlights segmentation, regional, and competitive insights to guide strategic planning. The focus is on translating evidence and policy trends into actionable guidance for clinicians, commercial teams, and policy makers charged with improving outcomes for patients with advanced CKD.

Critical transformative shifts in clinical, regulatory, and commercial dynamics that are reshaping late-stage chronic kidney disease treatment approaches and priorities

The late-stage CKD arena is experiencing several transformative shifts that are redefining how therapies are developed, delivered, and evaluated. Precision in patient stratification and the adoption of biomarkers are enabling more targeted intervention strategies that can delay progression and reduce dialysis initiation. Concurrently, advances in pharmacotherapies-ranging from refined erythropoiesis-stimulating approaches to more selective phosphate binders and modulators of mineral metabolism-are recalibrating treatment objectives toward reducing hospitalizations and cardiovascular events.

Care delivery is also evolving: there is a growing emphasis on home-based modalities and integrated care pathways that connect ambulatory surgical centers, dialysis facilities, and hospital networks with remote monitoring platforms to support patient adherence and early intervention. Payment models are shifting toward value-based arrangements that reward outcomes rather than volume, prompting manufacturers to demonstrate real-world effectiveness and to design risk-sharing agreements that align incentives with health systems and payers.

Finally, regulatory expectations and accelerated review pathways for therapies addressing unmet needs are encouraging sponsors to pursue novel endpoints and adaptive trial designs. As a result, companies that can demonstrate robust clinical differentiation, manageable safety profiles, and credible economic value will be best positioned to lead in the evolving marketplace.

Comprehensive analysis of how United States tariff measures implemented in 2025 have altered supply chain resilience, sourcing strategies, and commercial economics for CKD therapeutics

Tariff actions enacted in 2025 have exerted immediate and cascading pressures on global supply chains for therapeutics relevant to late-stage chronic kidney disease. Manufacturers sourcing active pharmaceutical ingredients, specialty excipients, or finished formulations from impacted jurisdictions have experienced higher landed costs, prompting finance and procurement teams to reassess sourcing strategies and inventory buffers. In response, firms have accelerated nearshoring, diversified supplier bases, and increased investments in supply chain visibility tools to mitigate exposure and ensure continuity of critical products such as injectables and dialysis-related disposables.

Commercial teams must now account for the tariff-driven cost implications when designing pricing and contracting strategies. Negotiations with hospital systems and dialysis networks are increasingly centered on total cost of care considerations, with buyers demanding greater transparency around cost drivers and suppliers exploring bundled offerings that combine product with services to preserve access. Smaller manufacturers face heightened pressure as compressed margins and elevated compliance burdens make it more challenging to absorb tariff-related increases without transferring costs to providers or payers.

Regulatory and policy stakeholders are also responding. There is a renewed focus on strategic stockpiles for essential renal care products, expedited approvals for alternate suppliers, and discussions around tariff exemptions for life-sustaining medicines. For industry leaders, proactive scenario planning that models tariff impacts across sourcing, manufacturing, and go-to-market channels will be crucial to sustain supply reliability and to maintain competitive positioning in a tighter cost environment.

Deep segmentation insights revealing how treatment types, disease stages, care settings, channels, payers, mechanisms, and formulations jointly dictate strategy and value realization

A nuanced segmentation framework reveals distinct demand drivers and commercial levers across treatment categories, disease stages, care settings, distribution channels, payer types, mechanisms of action, and formulations. Treatment modality distinctions separate dialysis, pharmacotherapy, and transplantation pathways, with pharmacotherapy further differentiated by antihypertensives, erythropoiesis-stimulating agents, phosphate binders, and vitamin D analogs; this split underscores how therapeutic purpose and expected outcomes shape clinical adoption and commercialization strategies. Disease stage segmentation into Stage 3, Stage 4, and Stage 5 provides a clinical roadmap for timing intervention, with Stage 3 and Stage 4 representing windows for slowing progression and Stage 5 demanding readiness for renal replacement therapies and complex care coordination.

End-user segmentation, spanning ambulatory surgical centers, dedicated dialysis centers, home care settings, and acute-care hospitals, highlights the importance of designing delivery models and support services that match the operational realities and procurement practices of each setting. Distribution channels including hospital pharmacy, online pharmacy, and retail pharmacy create different patient access pathways and influence adherence, continuity of care, and margin structures. Payer segmentation among government insurance, out-of-pocket payers, and private insurance reveals the need for differentiated reimbursement strategies and value dossiers that address affordability, coverage criteria, and prior authorization hurdles.

Mechanism-of-action categories such as erythropoiesis stimulation, phosphate binding, renin-angiotensin-aldosterone system inhibition, and vitamin D receptor activation clarify therapeutic positioning and combination potential, guiding clinical development and real-world evidence generation. Formulation distinctions between injectable and oral products affect administration logistics, patient preference, and channel economics, requiring manufacturers to align patient support programs and distribution partnerships accordingly. Together, these segmentation dimensions form a holistic picture that can inform product prioritization, targeted clinical evidence generation, and adaptive commercial models tailored to each intersection of clinical need and care setting.

Regional intelligence summarizing how Americas, Europe Middle East & Africa, and Asia-Pacific markets diverge in adoption, reimbursement, and strategic entry considerations

Regional dynamics shape where innovation gains traction and how therapeutic strategies must be adapted. In the Americas, mature reimbursement frameworks and integrated care systems tend to favor rapid uptake of clinical innovations that demonstrate outcomes and cost offsets, while established dialysis networks and transplant programs create concentrated demand centers. Payor negotiations and health technology assessment processes in this region incentivize robust real-world evidence and outcomes-based contracting to secure placement.

Europe, Middle East & Africa present diverse regulatory and reimbursement landscapes that span highly centralized procurement models and fragmented markets with variable access. In many countries within this region, procurement is influenced by national formularies and tender processes, prompting manufacturers to tailor pricing strategies and local evidence packages. The heterogeneity of healthcare infrastructure-from advanced tertiary centers to constrained rural settings-requires flexible distribution and support models that can bridge capability gaps.

Asia-Pacific demonstrates a mixture of high-growth adoption corridors and markets where access is constrained by funding limitations. Rapid demographic change and rising CKD prevalence in several countries create expanding demand for both pharmacotherapies and renal replacement services, while governments increasingly prioritize domestic manufacturing resilience and supply chain security. Across all regions, strategic market entry planning that accounts for regulatory timelines, local clinical guidelines, and payer expectations will be essential to convert clinical innovation into sustained patient impact.

Actionable competitive insights on differentiation, partnerships, manufacturing resilience, and evidence strategies that define leadership in late-stage CKD therapeutics

The competitive landscape in late-stage CKD therapeutics is characterized by a mix of legacy manufacturers with deep clinical experience, specialty biotech firms introducing mechanism-driven innovation, and emerging entrants focused on care delivery platforms and digital enablement. Incumbent players leverage established relationships with dialysis providers and hospitals, strong distribution networks, and extensive post-market safety data to sustain market presence. In contrast, newer entrants prioritize clear differentiation through novel mechanisms of action, pragmatic trial designs, and targeted patient segments where unmet need and potential clinical impact are greatest.

Strategic partnerships are increasingly common, combining biopharmaceutical innovation with supply chain specialists, digital health vendors, and specialty pharmacies to deliver comprehensive solutions that address adherence, monitoring, and patient support. Licensing and co-development agreements can accelerate time-to-market for promising compounds while mitigating commercialization risk. Manufacturing scale and quality assurance are also decisive competitive factors, with companies investing in manufacturing redundancy and regulatory compliance to safeguard supply and to satisfy large institutional buyers.

Companies that best align clinical value with payer-relevant outcomes, and that demonstrate credible plans to manage distribution and tariff-related cost challenges, will have an advantage. Leadership in late-stage CKD will depend not only on therapeutic efficacy but also on the ability to execute integrated commercial models that combine product, services, and real-world evidence generation.

Practical strategic recommendations for industry leaders to align evidence generation, supply chain resilience, and payer engagement to accelerate adoption and access

Companies should prioritize generating high-quality real-world evidence that links therapeutic interventions to reductions in hospitalization, delay of dialysis initiation, and improvements in patient-reported outcomes. This evidence will be essential to secure favorable reimbursement terms and to support outcomes-based contracting. Concurrently, manufacturers must design patient-centric support programs that address adherence, multimorbidity management, and transitions between care settings, particularly for therapies that shift care from hospital to home.

From an operational perspective, diversifying supply chains and instituting flexible sourcing strategies will reduce vulnerability to geopolitical and tariff-related shocks. Investment in manufacturing redundancy and nearshoring options should be weighed against long-term cost implications and the need for regulatory harmonization. Commercial teams must craft differentiated value propositions for key end-users-ambulatory surgical centers, dialysis centers, home care providers, and hospitals-while aligning distribution strategies across hospital, online, and retail pharmacy channels to maximize access and continuity of care.

Finally, engaging proactively with payers and policy makers can accelerate access pathways. Collaboration on pilot programs, shared-savings models, and corridor studies that demonstrate system-level benefits will open pathways to broader adoption. Leaders that integrate clinical excellence, supply chain resilience, and payer-aligned evidence programs will be positioned to convert innovation into sustained patient and commercial value.

Transparent research methodology detailing data triangulation, expert validation, and scenario analysis employed to ensure robust and actionable conclusions

This analysis synthesizes peer-reviewed clinical literature, regulatory guidance, public policy statements, and verified primary interviews with clinical specialists, payers, and procurement professionals to ensure a comprehensive understanding of late-stage CKD therapeutics. The methodological approach triangulates clinical trial outcomes with real-world utilization patterns and supply chain intelligence to derive actionable implications for commercialization and policy. Qualitative inputs from frontline clinicians and care managers were used to contextualize adoption barriers and care pathway constraints, while supplier and distributor perspectives informed assessments of operational risk.

Analytical rigor was maintained through cross-validation of thematic findings against multiple independent sources and through scenario analyses that explored supply chain, tariff, and reimbursement contingencies. Where appropriate, sensitivity checks were applied to ensure conclusions remained robust across plausible variations in policy and clinical practice. Stakeholder feedback loops, including expert review rounds, were executed to refine interpretations and to surface practical recommendations. This layered methodology balances empirical evidence with practitioner insight to deliver conclusions tailored for decision-makers in industry and healthcare delivery.

Conclusive synthesis of strategic imperatives and stakeholder responsibilities to translate therapeutic innovation into improved outcomes for late-stage CKD patients

Late-stage CKD therapeutics are at an inflection point shaped by scientific advances, evolving care models, and shifting policy levers. Clinical innovation alone will not guarantee impact; success will hinge on integrating therapeutic differentiation with resilient supply chains, payer-aligned evidence generation, and delivery models that meet the operational realities of dialysis centers, hospitals, and home-based care. Tariff-induced cost pressures and geopolitical volatility underscore the need for proactive sourcing strategies and collaborative contracting solutions to preserve access to life-sustaining therapies.

For manufacturers, the imperative is clear: invest in real-world evidence generation, design flexible commercial models that address diverse end-user needs, and prioritize manufacturing and distribution strategies that mitigate systemic risk. For clinicians and health systems, there is an opportunity to leverage new therapeutics in conjunction with care pathway redesigns that reduce progression and improve patient-centered outcomes. Policy makers can further enable progress by aligning reimbursement incentives with value and by considering targeted measures to protect supplies of essential renal medicines. Together, these coordinated actions can transform late-stage CKD management toward better outcomes and more sustainable care delivery.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Late Stage Chronic Kidney Disease Therapeutics Market, by Treatment Type

  • 8.1. Dialysis
  • 8.2. Pharmacotherapy
    • 8.2.1. Antihypertensives
    • 8.2.2. Erythropoiesis-Stimulating Agents
    • 8.2.3. Phosphate Binders
    • 8.2.4. Vitamin D Analogs
  • 8.3. Transplantation

9. Late Stage Chronic Kidney Disease Therapeutics Market, by Disease Stage

  • 9.1. Stage 3
  • 9.2. Stage 4
  • 9.3. Stage 5

10. Late Stage Chronic Kidney Disease Therapeutics Market, by End-User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Dialysis Centers
  • 10.3. Home Care Settings
  • 10.4. Hospitals

11. Late Stage Chronic Kidney Disease Therapeutics Market, by Distribution Channel

  • 11.1. Offline
  • 11.2. Online

12. Late Stage Chronic Kidney Disease Therapeutics Market, by Mechanism Of Action

  • 12.1. Erythropoiesis Stimulation
  • 12.2. Phosphate Binding
  • 12.3. RAAS Inhibition
  • 12.4. Vitamin D Receptor Activation

13. Late Stage Chronic Kidney Disease Therapeutics Market, by Formulation

  • 13.1. Injectable
  • 13.2. Oral

14. Late Stage Chronic Kidney Disease Therapeutics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Late Stage Chronic Kidney Disease Therapeutics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Late Stage Chronic Kidney Disease Therapeutics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Late Stage Chronic Kidney Disease Therapeutics Market

18. China Late Stage Chronic Kidney Disease Therapeutics Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbbVie Inc.
  • 19.6. Akebia Therapeutics, Inc.
  • 19.7. Amgen Inc.
  • 19.8. Ardelyx, Inc.
  • 19.9. Astellas Pharma Inc.
  • 19.10. AstraZeneca PLC
  • 19.11. Bayer AG
  • 19.12. Boehringer Ingelheim International GmbH
  • 19.13. Chinook Therapeutics, Inc.
  • 19.14. Eli Lilly and Company
  • 19.15. FibroGen, Inc.
  • 19.16. Gilead Sciences, Inc.
  • 19.17. GlaxoSmithKline PLC
  • 19.18. KBP Biosciences Co., Ltd.
  • 19.19. Maze Therapeutics, Inc.
  • 19.20. Novartis AG
  • 19.21. Novo Nordisk A/S
  • 19.22. Pfizer Inc.
  • 19.23. ProKidney, Inc.
  • 19.24. Travere Therapeutics, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DIALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DIALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DIALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY ERYTHROPOIESIS-STIMULATING AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY ERYTHROPOIESIS-STIMULATING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY ERYTHROPOIESIS-STIMULATING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY PHOSPHATE BINDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY PHOSPHATE BINDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY PHOSPHATE BINDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY VITAMIN D ANALOGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY VITAMIN D ANALOGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY VITAMIN D ANALOGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY TRANSPLANTATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY TRANSPLANTATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY TRANSPLANTATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY STAGE 3, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY STAGE 3, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY STAGE 3, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY STAGE 4, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY STAGE 4, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY STAGE 4, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY STAGE 5, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY STAGE 5, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY STAGE 5, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DIALYSIS CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DIALYSIS CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DIALYSIS CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY ERYTHROPOIESIS STIMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY ERYTHROPOIESIS STIMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY ERYTHROPOIESIS STIMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY PHOSPHATE BINDING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY PHOSPHATE BINDING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY PHOSPHATE BINDING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY RAAS INHIBITION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY RAAS INHIBITION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY RAAS INHIBITION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY VITAMIN D RECEPTOR ACTIVATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY VITAMIN D RECEPTOR ACTIVATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY VITAMIN D RECEPTOR ACTIVATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 149. GCC LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GCC LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. GCC LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 152. GCC LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 153. GCC LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 154. GCC LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. GCC LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 156. GCC LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 173. G7 LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. G7 LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. G7 LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 176. G7 LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 177. G7 LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 178. G7 LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. G7 LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 180. G7 LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 181. NATO LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. NATO LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. NATO LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 184. NATO LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 185. NATO LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 186. NATO LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 187. NATO LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 188. NATO LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED STATES LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 195. UNITED STATES LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. CHINA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY PHARMACOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 203. CHINA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. CHINA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA LATE STAGE CHRONIC KIDNEY DISEASE THERAPEUTICS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)